Get the Stockscreener App
6.80
3.27%
-0.23
After Hours:
6.80
Acurx Pharmaceuticals Inc stock is traded at $6.80, with a volume of 70,332.
It is down -3.27% in the last 24 hours and up +65.05% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$7.03
Open:
$7.02
24h Volume:
70,332
Relative Volume:
0.15
Market Cap:
$10.78M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-5.913
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-9.09%
1M Performance:
+65.05%
6M Performance:
-8.80%
1Y Performance:
-83.17%
1-Day Range:
$6.61
$7.11
1-Week Range:
$6.61
$7.98
52-Week Range:
$3.80
$41.00
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
6.80 | 11.14M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
How Acurx Pharmaceuticals Inc. stock responds to policy changesWeekly Risk Report & Real-Time Volume Trigger Notifications - Trung tâm Dự báo KTTV quốc gia
Can Acurx Pharmaceuticals Inc. stock attract ESG capital inflowsMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Can swing trading help recover from Acurx Pharmaceuticals Inc. lossesTrade Ideas & Low Risk Investment Opportunities - newser.com
What Fibonacci levels say about Acurx Pharmaceuticals Inc. reboundJuly 2025 Highlights & High Accuracy Investment Entry Signals - newser.com
Multi factor analysis applied to Acurx Pharmaceuticals Inc.July 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
Acurx Pharmaceuticals Inc Stock Analysis and ForecastEarnings Season Recap & Small Investment Trading Tips - earlytimes.in
Quantitative breakdown of Acurx Pharmaceuticals Inc. recent moveQuarterly Portfolio Review & Low Volatility Stock Suggestions - newser.com
Can Acurx Pharmaceuticals Inc. (3ZO) stock test all time highsChart Signals & High Win Rate Trade Alerts - newser.com
Will Acurx Pharmaceuticals Inc. stock split attract more investorsJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
How Acurx Pharmaceuticals Inc. (3ZO) stock reacts to fiscal policiesMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Why retail investors favor Acurx Pharmaceuticals Inc. stockWeekly Risk Report & High Conviction Trade Alerts - newser.com
Acurx Pharmaceuticals Inc.’s volatility index tracking explainedMarket Volume Summary & Weekly Momentum Stock Picks - newser.com
New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group - Kansas City Star
Acurx Pharmaceuticals, Inc.Common Stock (NQ: ACXP - FinancialContent
Acurx Pharmaceuticals (NASDAQ:ACXP) Raised to Hold at Wall Street Zen - Defense World
Acurx Pharmaceuticals granted Australian patent for antibiotics - Investing.com Australia
Acurx Pharmaceuticals granted Australian patent for antibiotics By Investing.com - Investing.com Nigeria
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors - Stock Titan
Measuring Acurx Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real? - ts2.tech
What drives Acurx Pharmaceuticals Inc stock pricePrice-to-Earnings Ratio Insights & High Return Market Tips - earlytimes.in
Pharma Boom: Acurx on the Rise - StocksToTrade
ACXP’s Steady Climb: New Developments? - timothysykes.com
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions - ts2.tech
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events - Corpus Christi Caller-Times
Will breakout in Acurx Pharmaceuticals Inc. lead to full recoveryPortfolio Update Summary & Daily Technical Stock Forecast Reports - newser.com
How supply shortages influence Acurx Pharmaceuticals Inc. (3ZO) stockInsider Buying & Weekly Stock Performance Updates - newser.com
Acurx Pharmaceuticals Inc. stock trendline breakdownChart Signals & Long-Term Investment Growth Plans - newser.com
Will Acurx Pharmaceuticals Inc. stock outperform Nasdaq indexJuly 2025 Earnings & Precise Buy Zone Identification - newser.com
New to The Street to Broadcast Nationwide on Bloomberg Tonight at 6:30 PM EST - Tacoma News Tribune
Acurx Pharmaceuticals (NASDAQ:ACXP) Lowered to Sell Rating by Wall Street Zen - Defense World
Will Acurx Pharmaceuticals Inc. (3ZO) stock return to pre crash levels2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com
Chart overlay techniques for tracking Acurx Pharmaceuticals Inc.2025 Support & Resistance & Consistent Profit Alerts - newser.com
Acurx Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Acurx Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):